Seliciclib (CYC202 or r-roscovitine) is novel cell cycle drug belonging to the Cyclin Dependent Kinase
(CDK) inhibitor class.
Paracelsian's patented CDK assays measure the concentration of at least one cyclin dependent kinase
in the blood, plasma or serum of an animal or human, and correlates that concentration to the presence of abnormal cellular proliferation or tumor development in any tissue of the organism from which the sample was obtained.
Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase
Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients" (Abstract # 3966, Poster board #: III-745)
It is claimed to be a selective cyclin dependent kinase
inhibitor that will decrease the progress of cancer by inhibiting two proteins called cyclin dependent kinase
4 and 6 (CDK4/6).
There is compelling scientific rationale to use TK as a biomarker for drugs that disrupt cell cycle regulation, such as Cyclin Dependent Kinase
According to the company, the revenue is a UK grant to progress CYC065, its Cyclin Dependent Kinase
inhibitor, to IND.
Seliciclib, Cyclacel's orally available cyclin dependent kinase
(CDK) inhibitor, is currently being tested as a single agent in the Phase 2b APPRAISE trial in patients with non-small cell lung cancer and in a Phase 2 study in patients with nasopharyngeal cancer.